Leukemia 2015 Oct 07
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.   

Related Questions

Would you consider Dara-CyBorD or a MM triplet/quadruplet such as VRd or Dara-VRd?